GRF(1-29) raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-13. Anything still debated is marked as such rather than presented as settled.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
"Clinical evaluation of De Marco formula as an adjunctive therapy for infected ischemic diabetic foot: a prospective randomized controlled trial". Can J Clin Pharmacol. 16 (2): e381–91. PMID 19966380. DeMarco Peter. "Treatment of Macular Degeneration." United States Patent Application, US 20040180090.
== Historical uses == Especially in medieval times, the end of a chain could be attached to a chain tower or boom tower. This allowed safe raising or lowering of the chain, as they were often heavily fortified. By raising or lowering a chain or boom, access could be selectively granted rather than simply rendering the stretch of water completely inaccessible. The raising and lowering could be accomplished by a windlass mechanism or a capstan. Booms or chains could be broken by a sufficiently large or heavy ship, and this occurred on many occasions, including the siege of Damietta, the raid on the Medway and the Battle of Vigo Bay.A Frequently, however, attackers instead seized the defences and cut the chain or boom by more conventional methods. The boom at the siege of Derry, for example, was cut by sailors in a longboat. As a key portion of defences, booms were usually heavily defended. This involved shore-based chain towers, artillery batteries, or forts. In the Age of Sail, a boom protecting a harbour could have several ships defending it with their broadsides, discouraging assaults on the boom. On some occasions, multiple booms spanned a single stretch of water.
Trump and his administration's Make America Healthy Again agenda promoted various anti-science and anti-vaccine claims, which led to a resurgence of whooping cough and measles. They alleged they were working against Big Pharma. On November 14, Trump announced that he would nominate Robert F. Kennedy Jr. for Health and Human Services Secretary. This was controversial given Kennedy's repeated endorsement of anti-vaccine conspiracy theories. The director of the American Public Health Association, America's largest organization of public health professionals, said, "He is not competent by training, management skills, temperament or trust to have this job." On February 18, Trump signed an executive order calling for the policy recommendations for reducing the out-of-pocket costs of In Vitro Fertilisation. On February 25, Trump signed an executive order to improve healthcare cost transparency.
=== Co-attraction === Co-attraction between collectively migrating cells is the process by which cells of the same type secrete chemo-attractant (e.g. C3a in neural crest cells), that stimulates other cells in the group that have the receptors to that chemo-attractant. Cells sense the secreted substrate and respond to the stimulation by moving towards each other's and maintain high cell density.
Sources: en.wikipedia.org
When transmembrane proteins are translated from RNA they have start-transfer-sequences and stop-transfer-sequences before their posttranslational modifications occurs. The start-transfer-sequence is used to recruit a signal recognition particle(SRP) which consequently stops translation until it binds to a SRP-receptor on the surface of the lipid bilayer. Translocons are channels in the membrane which allow proteins to be moved across the membrane and the Ribosome synthesizes the polypeptide directly through it. The start-transfer-sequence is attached to the Translocon and is cleaved posttranslationally along with the stop-transfer-sequence. Many other complex pathways for embedding proteins exist, specific to eukaryotes and prokaryotes respectively.
A liquid in an area of low pressure (vacuum) vaporizes and forms bubbles, which then collapse as they enter high pressure areas. This causes liquid to fill the cavities left by the bubbles with tremendous localized force, eroding any adjacent solid surface.
According to some officials, Cubans were being removed from their posts in Venezuela's General Directorate of Military Counterintelligence (DGCIM). On 6 January 55 military deaths were confirmed: the victims were 32 Cubans and 23 Venezuelans. Both the countries released on the same day the identities of the killed soldiers. Also on 6 January, military forces posted a video on social media in honor of 24 soldiers killed during the attack. Attorney General Tarek William Saab indicated that dozens of military personnel and civilians were killed and the total number is still under investigation. A day later, Diosdado Cabello said that 100 persons died during the bombing. Independent monitors reported as of 7 January Venezuelan military casualties as of 6 January of 42 or 43 soldiers (mostly at Fort Tiuna), in addition to the 32 Cuban military personnel, and 2 civilians. On 16 January, Venezuelan defense minister Vladimir Padrino López, said that 47 soldiers, including 9 women, were killed during the attack. Acting president Delcy Rodríguez declared seven days of mourning for the soldiers killed during the attack. The remains of the Cuban fatalities were repatriated on 15 January. They received a mass funeral ceremony in Havana upon arrival. In Catia La Mar, strikes hit a three-story civilian apartment complex, killing one person, seriously injuring another, and destroying the exterior wall. Yohana Rodríguez Sierra, a Colombian citizen, was reported as a civilian fatality in El Hatillo.
==== Nanowire compositions ==== Scientists have devised a large number of nanowire compositions with controlled length, diameter, doping, and surface structure by using vapor and solution phase strategies. These oriented single crystals are being used in semiconductor nanowire devices such as diodes, transistors, logic circuits, lasers, and sensors. Since nanowires have a one-dimensional structure, meaning a large surface-to-volume ratio, the diffusion resistance decreases. In addition, their efficiency in electron transport which is due to the quantum confinement effect, makes their electrical properties be influenced by minor perturbation. Therefore, the use of these nanowires in nanosensor elements increases the sensitivity in electrode response. As mentioned above, the one-dimensionality and chemical flexibility of the semiconductor nanowires make them applicable in nanolasers. Peidong Yang and his co-workers have done some research on the room-temperature ultraviolet nanowires used in nanolasers. They have concluded that using short wavelength nanolasers has applications in different fields such as optical computing, information storage, and microanalysis.
Salvinorin A is a trans-neoclerodane diterpenoid with the chemical formula C23H28O8. Unlike other known opioid-receptor ligands, salvinorin A is not an alkaloid, as it does not contain a nitrogen atom.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.